Workflow Orchestration for Gene Therapy AAV Clinical Trial

Data Characteristics

Gene therapy AAV clinical trial prescreening data primarily comes from preclinical research reports, toxicology studies, gene sequencing results, biomarker detection, and patient medical history records. This data often mixes unstructured documents (e.g., PDF experimental reports, clinical notes) and semi-structured data (e.g., CSV or JSON gene mutation lists, protein expression profiles). Data update frequency is relatively low, mainly concentrated around the release of different clinical trial phase reports. Document structures are complex, containing extensive specialized terminology, charts, and references. Field specificity includes vector serotype (e.g., AAV9), transgene expression levels (e.g., copies/cell), immunogenicity indicators (e.g., neutralizing antibody titer), and patient-specific genotype information (e.g., SNP ID). Units, in addition to standard concentration and dosage units, involve genomics-specific counting units and biological activity units.

Constraints Imposed by Data Characteristics on Workflow Orchestration

The highly specialized and complex nature of gene therapy AAV data places strict demands on workflow orchestration. Preprocessing unstructured documents requires robust text extraction and entity recognition capabilities to accurately extract key information such as vector dose or treatment duration. The low data update frequency means the workflow needs version management features to ensure each prescreening is based on a clear data snapshot. Complex document structures require parsing modules within the workflow to handle multi-paragraph, table, and chart mixed content, and to identify contextual relationships. Field and unit specificity, such as AAV serotype and gene copy number, requires the workflow to support custom data types and validation rules during data standardization and validation. This directly impacts subsequent logical judgments and conditional branching settings, for example, deciding whether to proceed with the next round of screening based on neutralizing antibody titer levels.

Configuration Settings

Configuration Item	Recommended Value	Rationale for this Recommendation
`Chunk size`	`800–1200 characters`	Accommodates long sentences and complex descriptions in gene reports, ensuring semantic completeness.
`Recall count`	`Top 10 entries`	Increases the probability of capturing relevant genotypes and vector information from vast clinical literature.
`Similarity threshold`	`0.75`	Balances high recall and low false positives, filtering out irrelevant preclinical data.
`maxContext`	`8192 token`	Accommodates complete clinical trial protocols or gene sequencing report fragments, reducing context truncation.
`PARSE_FILE_TIMEOUT_SECONDS`	`300 seconds`	Allows processing of large PDF experimental reports and attachments, preventing parsing timeouts.
`Rerank result count`	`Top 5 entries`	Focuses on the most relevant patient characteristics or AAV vector optimization suggestions, improving decision efficiency.

Common Pitfalls

During workflow execution, patient genotype matching results are empty because the text extraction module failed to correctly identify the SNP ID format in the report.
Clinical trial screening process triggers an exception because the global variable AAV_SEROTYPE was not correctly passed or reset when switching between different APPs.
When generating the prescreening report, the vector dose unit is incorrect because the data standardization module did not uniformly convert mg/kg and IU/dose.

Verification Steps

Check workflow logs to confirm that all text extraction nodes successfully identified and extracted vector name and key gene loci from the report.
Perform end-to-end testing with a set of simulated data with known genotypes. Verify that prescreening results match expectations and validate conditional branching logic.
Examine the workflow's output report. Ensure all biomarker values, gene copy numbers, and other field units comply with industry standards.

The values provided are common starting points and should be measured against your own samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.